entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 22:57:50 - browse：1

A person wears a headset projecting a brain -- health tech coverage from STAT — Adobe

Just as a new wave of approved drugs for Alzheimer’s disease reaches patients, medical device company Cognito Therapeutics has raised a fresh $35 million to advance its alternative treatment for the neurodegenerative disease.

With the new Series B extension funding, the Cambridge, Mass.-based company has now raised $128 million to develop its headset that uses gamma frequency light and sound stimulation to combat the cognitive decline that’s the hallmark of Alzheimer’s. Cognito is currently undertaking a large study of the treatment and CEO Brent Vaughan told STAT he expects the company to complete the trial and submit data to the Food and Drug Administration for review by the end of 2025.

While under treatment, patients use the device for one hour per day in their homes. The light and sound is supposed to stimulate brain activity that’s disrupted by neurodegenerative conditions, potentially helping to preserve brain structure.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： House transparency, PBM reform bill gains bipartisan support

focus

hotspot

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

Stem cell treatment guidelines are released by FDA

Pharma budget tightening trickles down to Doximity

Humana sues Biden admin over Medicare Advantage audit rule

Amazon on where the company's health care bets are headed next

Where are patients getting their prescriptions for GLP

knowledge

entertainment

Wikipedia

How one medical school became remarkably diverse

Novo acquires Inversago for up to $1 billion

BioMarin wins approval for gene therapy to treat hemophilia A

Some of the ways extreme heat will change life as we know it

BioMarin wins approval for gene therapy to treat hemophilia A

Illumina names Agilent executive as new CEO

How one medical school became remarkably diverse

Newly revealed memo details efforts to keep Trump in power following election loss

Medicare details structure of new drug price negotiation program

Some of the ways extreme heat will change life as we know it

entertainment

Listen: Your guide to Wegovy's blockbuster heart study

Covid's long

Why Novartis is changing the name of its research labs

Advances in CAR

What drug price negotiations mean for Medicare Part D

The 10 drugs up first for Medicare price negotiation

hotspot

focus

hotspot

explore